Table 2 Therapeutic schedule and outcomes of the 13 patients with RMS and bone marrow metastasis
Case | Treatment | Take | From onset | Main site of | Treatment | Follow-up | Outcome |
|---|---|---|---|---|---|---|---|
Temozolomide | to progression(m) | Progression | after relapse | (m) | |||
1 | CT | NO | 3 | Primate site, lung, intracalvarium | CT | 6 | death |
2 | CT + ST | NO | 6 | Primate site,lung,intracalvarium | CT | 8 | death |
3 | CT + RT + ST | NO | 6 | Intracalvarium | CT + TT | 8 | death |
4 | CT + RT + ST | NO | 15 | Primary site, Lymph node | CT | 27 | death |
5 | CT + RT + ST | NO | 13.5 | Intracalvarium | CT + ST + RT + CART | 36.5 | death |
6 | CT + RT | Yes | 4.3 | Intracalvarium | CT | 8 | death |
7 | CT + RT + ST | Yes | 4.8 | Lung, bone marrow | CT | 16 | death |
8 | CT + RT + ST | Yes | 9 | Bone marrow, Intracalvarium | CT + ST + RT + TT | 12.3 | death |
9 | CT + RT + ST | Yes | 19 | Bone | CT + RT | 21 | Survive |
10 | CT + RT + ST | Yes | 21.2 | Primary site, lymph nodes | CT + ST + RT | 27.2 | survive |
11 | CT + RT + ST | Yes | 12 | Lymph nodes | CT + ST + RT | 27. 6 | survive |
12 | CT + RT + ST | Yes | 28.3 | Primary site | CT + ST + RT + TT | 46.2 | survive |
13 | CT + RT + ST | Yes | / | / | / | 14.5 | survive |